Acadia Pharmaceuticals Inc. filings document the regulatory record for a commercial biopharmaceutical company focused on neurological and rare diseases. Recent Form 8-K reports furnish quarterly and annual operating results, product-sales disclosures for NUPLAZID and DAYBUE, corporate presentations and Regulation FD materials, and updates tied to research-and-development leadership.
Proxy and governance filings describe board composition, committee service, director compensation, executive compensation, equity-incentive awards and annual meeting matters. The filings also record board appointments and resignations, non-employee director compensation under equity plans, and other material-event disclosures affecting Acadia’s governance and capital structure.
ACADIA Pharmaceuticals reported modest revenue growth but sharply lower profit for the quarter ended March 31, 2026. Net product sales reached $268.1 million, up from $244.3 million a year earlier, driven by NUPLAZID at $166.9 million and DAYBUE at $101.2 million.
Despite higher sales, net income fell to $3.6 million from $19.0 million as selling, general and administrative expenses rose to $171.0 million, reflecting heavier commercial investment, while research and development spending remained roughly flat at $76.9 million. Cash, cash equivalents and investment securities totaled $851.5 million, and operating cash flow improved to $34.0 million, indicating the company is funding growth while maintaining a strong liquidity position.
Acadia Pharmaceuticals reported first quarter 2026 total revenues of $268 million, up 10% from $244 million a year earlier, driven by neurology drugs NUPLAZID and DAYBUE. GAAP net product sales were $167 million for NUPLAZID, up 5% year-over-year, and $101 million for DAYBUE, up 20% year-over-year, helped by the U.S. launch of the DAYBUE STIX formulation.
Research and development expenses were $77 million, roughly flat versus 2025, while selling, general and administrative expenses rose to $171 million from $126 million as the company invested behind commercial growth. Net income declined to $3.6 million, or $0.02 per diluted share, from $19.0 million, reflecting higher operating costs. Cash, cash equivalents and investment securities totaled $851 million as of March 31, 2026. Acadia reaffirmed its full-year 2026 guidance, including total revenues of $1.22–$1.28 billion, NUPLAZID net product sales of $760–$790 million, DAYBUE net product sales of $460–$490 million, and R&D and SG&A expense ranges. The company also highlighted upcoming Phase 2 topline results for remlifanserin in Alzheimer’s disease psychosis expected between August and October 2026.
ACADIA PHARMACEUTICALS principal accounting officer James Kihara exercised and vested equity awards and sold shares to cover taxes. On May 1, 2026, he exercised 2,596 restricted stock units, receiving the same number of common shares at $0.00 per share. On May 4, 2026, 1,332 common shares were sold at a weighted average price of $21.79, with footnotes stating these mandatory sales were solely to cover withholding taxes and tax-related items in connection with the RSU vesting and intended to meet Rule 10b5-1(c) requirements. After these transactions, he directly held 29,129 common shares.
ACADIA PHARMACEUTICALS INC EVP and CFO Mark C. Schneyer reported routine equity compensation activity involving restricted stock units and related tax sales. On May 1, 2026, restricted stock units representing 6,815 shares of common stock vested and were exercised at $0.00 per share.
On May 4, 2026, 3,506 shares of common stock were sold in open-market transactions at a weighted average price of $21.79 per share to cover withholding taxes and tax-related items tied to this vesting, consistent with Rule 10b5-1(c) requirements. After these transactions, Schneyer directly held 66,145 shares of common stock.
Acadia Pharmaceuticals Inc. announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., its Head of Research and Development. Dr. Thompson, who joined the company in 2024, is retiring for personal reasons and will remain in her role during a transitional period until a successor is appointed.
After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to support continuity, including through the planned readout of the Phase 2 clinical study of remlifanserin in Alzheimer’s disease psychosis and into early Phase 3 execution. Ongoing clinical trials, including Phase 2 studies of remlifanserin in Alzheimer’s disease psychosis and Lewy Body Dementia Psychosis, are continuing as planned, and the company has begun a search for a new Head of Research and Development.
Vanguard Portfolio Management reports beneficial ownership of 8,781,007 shares of ACADIA Pharmaceuticals Inc Common Stock. The filing states this equals 5.15% of the class, with 109,362 shares subject to sole voting power and 8,781,007 shares subject to sole dispositive power as of 03/31/2026. The disclosure describes holdings managed across Vanguard Portfolio Management LLC and affiliated business divisions.
Acadia Pharmaceuticals is holding its 2026 annual stockholder meeting virtually on May 29, 2026 at 8:00 a.m. Pacific time. Stockholders of record as of April 14, 2026 may vote online on several key items.
Proposals include electing three Class I directors to serve until the 2029 meeting, an advisory “say-on-pay” vote on executive compensation, and ratification of Ernst & Young LLP as independent auditor for 2026. The company also seeks approval to amend its 2024 Equity Incentive Plan to increase the shares authorized for issuance by 5,209,670, adjust the counting ratio for full-value awards, and raise the maximum shares available for incentive stock options. The Board recommends voting “FOR” all four proposals.
ACADIA Pharmaceuticals EVP and CFO Mark C. Schneyer reported routine equity compensation activity involving restricted stock units and related tax sales. On April 5, 5,276 restricted stock units were exercised into 5,276 shares of common stock at a conversion price of $0.00 per share, increasing his direct holdings. The restricted stock units vest in four equal annual installments beginning April 5, 2023.
On April 7, 2,709 shares of common stock were sold at $22.20 per share, leaving Schneyer with 62,836 shares directly owned after the transactions. According to the disclosure, these mandatory sales were made to cover withholding taxes and related items in connection with the RSU vesting and are intended to comply with Rule 10b5-1(c) under the Exchange Act.
ACADIA PHARMACEUTICALS’ principal accounting officer, James Kihara, reported routine RSU vesting and related tax sales. On April 5, 2026, 2,010 restricted stock units were converted into 2,010 shares of common stock at $0.00 per share. The same RSU grant vests in four equal annual installments beginning April 5, 2023.
On April 7, 2026, 1,030 of these shares were sold in open-market transactions at a weighted-average price of $22.20 per share, with actual prices ranging from $22.07 to $22.20. A footnote states these mandatory sales were made to cover withholding taxes and related tax items in connection with the RSU vesting and are intended to comply with Rule 10b5-1(c). After these transactions, Kihara directly holds 27,865 shares of Acadia common stock.